Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, due to alleged misleading statements regarding the company's manufacturing and regulatory prospects [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Inovio made false and misleading statements about its CELLECTRA device manufacturing and the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [5]. - The lawsuit alleges that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [5]. - Investors are encouraged to join the class action without any out-of-pocket fees through a contingency fee arrangement [2][3]. Group 2: Firm Background - Rosen Law Firm specializes in securities class actions and has a strong track record, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - The founding partner of Rosen Law Firm was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and reputation in the field [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, Inc. related to alleged violations of federal securities laws, particularly concerning misleading statements about the company's manufacturing and regulatory processes for its INO-3107 treatment [3][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Inovio to contact them to discuss their legal options [1]. - A federal securities class action has been filed against Inovio, with a deadline of April 7, 2026, for investors to seek the role of lead plaintiff [3]. - The complaint alleges that Inovio and its executives made false statements regarding the manufacturing of the CELLECTRA device and the prospects of the INO-3107 Biologics License Application (BLA) [5]. Group 2: Regulatory Developments - On December 29, 2025, the FDA accepted Inovio's BLA for INO-3107 but indicated that the company did not provide sufficient information for accelerated approval [6]. - Inovio announced it does not plan to pursue approval under the standard review timeline and will seek a meeting with the FDA to discuss options for accelerated approval [6]. - Following the FDA's announcement, Inovio's stock price dropped by $0.56, or 24.45%, closing at $1.73 per share [7].

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals for alleged violations of securities laws due to misleading statements regarding its manufacturing capabilities and regulatory submissions [1][4]. Group 1: Lawsuit Details - The Schall Law Firm is representing investors in a class action lawsuit against Inovio Pharmaceuticals for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased Inovio's securities between October 10, 2023, and December 26, 2025, are encouraged to participate in the lawsuit before the deadline of April 7, 2026 [2]. - The lawsuit claims that Inovio made false and misleading statements about its CELLECTRA device and the likelihood of filing the INO-3107 Biologics License Application (BLA) by the second half of 2024 [4]. Group 2: Allegations Against Inovio - The complaint alleges that Inovio suffered from manufacturing deficiencies and failed to provide sufficient evidence for an FDA priority review or accelerated approval for its BLA [4]. - As a result of these misleading statements, investors experienced damages when the truth about Inovio's situation was revealed [4].

Core Viewpoint - A class action has been filed against Inovio Pharmaceuticals, Inc. for allegedly misleading investors regarding the approval process of its CELLECTRA device and the INO-3107 Biologics License Application (BLA) [1][2]. Group 1: Allegations and Issues - The complaint alleges that Inovio failed to disclose deficiencies in the manufacturing of its CELLECTRA device, which impacted the likelihood of submitting the INO-3107 BLA to the FDA by the previously projected timeline [2]. - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [2]. - On August 8, 2024, Inovio announced a delay in the submission of the INO-3107 BLA to mid-2025 due to manufacturing issues, resulting in a stock price drop of $0.27 per share, or 3.1%, closing at $8.44 on August 9, 2024 [3]. Group 2: Regulatory Developments - On December 29, 2025, Inovio announced that the FDA accepted the INO-3107 BLA for standard review rather than accelerated review, as the company did not provide adequate information for the latter [4]. - Following this announcement, Inovio's stock price fell by $0.56 per share, or 24.45%, closing at $1.73 on December 29, 2025 [4]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Inovio, with a deadline to submit papers to serve as lead plaintiff by April 7, 2026 [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Inovio Pharmaceuticals, Inc. securities during the specified Class Period, highlighting potential misstatements and failures to disclose critical information regarding the company's regulatory submissions and product manufacturing [1][5]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased Inovio securities between October 10, 2023, and December 26, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against Inovio - The lawsuit alleges that Inovio made false and misleading statements regarding the manufacturing quality of its CELLECTRA device [5]. - It is claimed that Inovio was unlikely to submit the INO-3107 Biologics License Application to the FDA by the second half of 2024 due to these deficiencies [5]. - The lawsuit also states that Inovio lacked sufficient information to justify the eligibility of INO-3107 for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. for alleged securities fraud, impacting investors who purchased shares between October 10, 2023, and December 26, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that Inovio made materially false and misleading statements regarding its business operations and prospects during the class period [1]. - Investors have until April 7, 2026, to file a lead plaintiff motion in the ongoing lawsuit [1]. - The complaint alleges that Inovio failed to disclose significant issues related to its CELLECTRA device manufacturing and the likelihood of timely FDA submission for its INO-3107 treatment [1]. Group 2: Stock Price Impact - Following the announcement of a delay in the BLA submission for INO-3107 due to manufacturing issues, Inovio's stock price fell by $0.27, or 3.1%, closing at $8.44 on August 9, 2024 [1]. - On December 29, 2025, after the FDA accepted the INO-3107 BLA on a standard review timeline, the stock price dropped by $0.56, or 24.45%, closing at $1.73 [1]. Group 3: Allegations of Misleading Information - The lawsuit alleges that Inovio overstated the regulatory and commercial prospects of INO-3107, leading to materially misleading statements about the company's business [1]. - Specific allegations include deficiencies in manufacturing for the CELLECTRA device and insufficient information to justify eligibility for FDA accelerated approval [1].

Core Viewpoint - Class action lawsuits have been filed against several publicly-traded companies, alleging that these companies made materially false and misleading statements regarding their business operations and financial prospects, leading to investor losses. Group 1: BlackRock TCP Capital Corp. (NASDAQ: TCPC) - The class period for BlackRock TCP Capital Corp. is from November 6, 2024, to January 23, 2026, with a lead plaintiff deadline of April 6, 2026 [2] - Allegations include failure to disclose that investments were not being timely valued, restructuring efforts were ineffective, unrealized losses were understated, and NAV was overstated, leading to misleading positive statements about the company's prospects [2] Group 2: Oracle Corporation (NYSE: ORCL) - The class period for Oracle Corporation is from June 12, 2025, to December 16, 2025, with a lead plaintiff deadline of April 6, 2026 [3] - Allegations state that Oracle's AI infrastructure strategy would lead to significant increases in capital expenditures without corresponding revenue growth, creating risks related to debt, credit rating, and cash flow, thus rendering positive statements misleading [3] Group 3: Paysafe Limited (NYSE: PSFE) - The class period for Paysafe Limited is from March 4, 2025, to November 12, 2025, with a lead plaintiff deadline of April 7, 2026 [4] - Allegations include significant exposure to a high-risk client, understated credit loss reserves, issues with higher risk Merchant Category Codes, and an inability to meet previously issued financial guidance for fiscal year 2025, leading to misleading positive statements [4] Group 4: Inovio Pharmaceuticals, Inc. (NASDAQ: INO) - The class period for Inovio Pharmaceuticals is from October 10, 2023, to December 26, 2025, with a lead plaintiff deadline of April 7, 2026 [5] - Allegations indicate deficiencies in manufacturing for Inovio's CELLECTRA device, unlikelihood of submitting the INO-3107 BLA to the FDA on time, and overstated regulatory and commercial prospects, resulting in misleading positive statements [6]

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from October 10, 2023, to December 26, 2025, seeking damages for investors who acquired Inovio securities during this time [1] Company Overview - Inovio Pharmaceuticals is a biotechnology company focused on developing DNA medicines to treat diseases, including those associated with human papilloma virus (HPV) [1] - The company's lead product candidate is INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV [1] Allegations and Misstatements - Defendants allegedly made materially false and misleading statements regarding Inovio's business and prospects, including: - Deficiencies in the manufacturing of the CELLECTRA device [1] - Unlikelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [1] - Insufficient information to justify eligibility for FDA accelerated approval or priority review [1] - Overstated regulatory and commercial prospects for INO-3107 [1] Stock Price Impact - Following the revelation of a manufacturing issue on August 8, 2024, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 on August 9, 2024 [1] - On December 29, 2025, after the FDA accepted the INO-3107 BLA on a standard review timeline, the stock price dropped by $0.56 per share, or 24.45%, closing at $1.73 [1]

Core Viewpoint - An investigation has been announced regarding Inovio Pharmaceuticals, Inc. for potential violations of federal securities laws affecting investors [1] Group 1 - The Law Offices of Howard G. Smith are representing investors who may have suffered losses in Inovio Pharmaceuticals, Inc. [1] - Investors are encouraged to contact the law firm to discuss potential claims for recovering losses [1]

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating Inovio Pharmaceuticals, Inc. for potential violations of federal securities laws, particularly concerning investor losses [1] Group 1 - The investigation is initiated on behalf of investors who may have lost money on Inovio Pharmaceuticals, Inc. [1] - The investigation follows the company's announcement made on August 8, 2024, after market hours [1]